These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23583454)

  • 21. Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems.
    Luethi D; Kolaczynska KE; Walter M; Suzuki M; Rice KC; Blough BE; Hoener MC; Baumann MH; Liechti ME
    J Psychopharmacol; 2019 Jul; 33(7):831-841. PubMed ID: 31038382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).
    Marusich JA; Antonazzo KR; Wiley JL; Blough BE; Partilla JS; Baumann MH
    Neuropharmacology; 2014 Dec; 87():206-13. PubMed ID: 24594476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.
    Blough BE; Landavazo A; Decker AM; Partilla JS; Baumann MH; Rothman RB
    Psychopharmacology (Berl); 2014 Oct; 231(21):4135-44. PubMed ID: 24800892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
    Verrico CD; Miller GM; Madras BK
    Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.
    Negus SS; Banks ML
    Curr Top Behav Neurosci; 2017; 32():119-131. PubMed ID: 27696217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.
    Baumann MH; Partilla JS; Lehner KR; Thorndike EB; Hoffman AF; Holy M; Rothman RB; Goldberg SR; Lupica CR; Sitte HH; Brandt SD; Tella SR; Cozzi NV; Schindler CW
    Neuropsychopharmacology; 2013 Mar; 38(4):552-62. PubMed ID: 23072836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicology of Synthetic Cathinone Analogs.
    Angoa-Pérez M; Anneken JH; Kuhn DM
    Curr Top Behav Neurosci; 2017; 32():209-230. PubMed ID: 27753008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
    Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
    Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological characterization of designer cathinones in vitro.
    Simmler LD; Buser TA; Donzelli M; Schramm Y; Dieu LH; Huwyler J; Chaboz S; Hoener MC; Liechti ME
    Br J Pharmacol; 2013 Jan; 168(2):458-70. PubMed ID: 22897747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
    Kolaczynska KE; Thomann J; Hoener MC; Liechti ME
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter.
    Gannon BM; Baumann MH; Walther D; Jimenez-Morigosa C; Sulima A; Rice KC; Collins GT
    Neuropsychopharmacology; 2018 Nov; 43(12):2399-2407. PubMed ID: 30305739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
    Shimazu S; Tsunekawa H; Yoneda F; Katsuki H; Akaike A; Janowsky A
    Eur J Pharmacol; 2003 Dec; 482(1-3):9-16. PubMed ID: 14659999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological characterization of ecstasy synthesis byproducts with recombinant human monoamine transporters.
    Pifl C; Nagy G; Berényi S; Kattinger A; Reither H; Antus S
    J Pharmacol Exp Ther; 2005 Jul; 314(1):346-54. PubMed ID: 15831439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction Profiles of Central Nervous System Active Drugs at Human Organic Cation Transporters 1-3 and Human Plasma Membrane Monoamine Transporter.
    Angenoorth TJF; Stankovic S; Niello M; Holy M; Brandt SD; Sitte HH; Maier J
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses.
    de Moura FB; Sherwood A; Prisinzano TE; Paronis CA; Bergman J; Kohut SJ
    Pharmacol Biochem Behav; 2021 Mar; 202():173112. PubMed ID: 33444603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profile of mephedrone analogs and related new psychoactive substances.
    Luethi D; Kolaczynska KE; Docci L; Krähenbühl S; Hoener MC; Liechti ME
    Neuropharmacology; 2018 May; 134(Pt A):4-12. PubMed ID: 28755886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system.
    Wilhelm CJ; Johnson RA; Lysko PG; Eshleman AJ; Janowsky A
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1142-51. PubMed ID: 15102929
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.
    Magee CP; German CL; Siripathane YH; Curtis PS; Anderson DJ; Wilkins DG; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2020 Aug; 374(2):273-282. PubMed ID: 32385092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related Behavior.
    Battisti UM; Sitta R; Harris A; Sakloth F; Walther D; Ruchala I; Negus SS; Baumann MH; Glennon RA; Eltit JM
    ACS Chem Neurosci; 2018 Jul; 9(7):1829-1839. PubMed ID: 29697951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Polytox" synthetic cathinone abuse: A potential role for organic cation transporter 3 in combined cathinone-induced efflux.
    Mayer FP; Schmid D; Holy M; Daws LC; Sitte HH
    Neurochem Int; 2019 Feb; 123():7-12. PubMed ID: 30248432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.